Business Wire

Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the ...
The American Journal of Managed Care

FRα Biomarker Testing in Patients With Ovarian Cancer

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...
WJHL-TV

ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting

WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative ...
Healio

VIDEO: Response seen with Rina-S in ovarian cancer despite FR-alpha expression levels

In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with advanced ovarian cancer, which were presented at Society of Gynecologic Oncology Annual ...